Search

Displaying results 5621 - 5630 of 10000 in total
  1. Pathway

    Cardiolipin Biosynthesis CL(20:4(5Z,8Z,11Z,14Z)/20:3(11Z,14Z,17Z)/20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z))

    smpdb.ca/view/SMP0248892
    Metabolic

    Last, cardiolipin synthase catalyzes the synthesis of cardiolipin by transferring a phosphatidyl group from a second CDP-diacylglycerol to PG. It requires a divalent metal cation cofactor.

    Drugs: NADH · Cytidine-5'-Triphosphate · sn-glycerol 3-phosphate · Pyrophosphoric acid · Dihydroxyacetone phosphate
  2. Pathway

    Cardiolipin Biosynthesis CL(18:4(6Z,9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z)/20:3(11Z,14Z,17Z)/18:4(6Z,9Z,12Z,15Z))

    smpdb.ca/view/SMP0250067
    Metabolic

    Last, cardiolipin synthase catalyzes the synthesis of cardiolipin by transferring a phosphatidyl group from a second CDP-diacylglycerol to PG. It requires a divalent metal cation cofactor.

    Drugs: NADH · Cytidine-5'-Triphosphate · sn-glycerol 3-phosphate · Pyrophosphoric acid · Dihydroxyacetone phosphate
  3. Pathway

    Cardiolipin Biosynthesis CL(18:4(6Z,9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z)/20:3(11Z,14Z,17Z))

    smpdb.ca/view/SMP0250085
    Metabolic

    Last, cardiolipin synthase catalyzes the synthesis of cardiolipin by transferring a phosphatidyl group from a second CDP-diacylglycerol to PG. It requires a divalent metal cation cofactor.

    Drugs: NADH · Cytidine-5'-Triphosphate · sn-glycerol 3-phosphate · Pyrophosphoric acid · Dihydroxyacetone phosphate
  4. Pathway

    Cardiolipin Biosynthesis CL(20:3(11Z,14Z,17Z)/20:4(5Z,8Z,11Z,14Z)/18:4(6Z,9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z))

    smpdb.ca/view/SMP0250387
    Metabolic

    Last, cardiolipin synthase catalyzes the synthesis of cardiolipin by transferring a phosphatidyl group from a second CDP-diacylglycerol to PG. It requires a divalent metal cation cofactor.

    Drugs: NADH · Cytidine-5'-Triphosphate · sn-glycerol 3-phosphate · Pyrophosphoric acid · Dihydroxyacetone phosphate
  5. Drug

    Vortioxetine

    go.drugbank.com/drugs/DB09068
    ApprovedInvestigational

    receptor, an agonist of 5-HT1A, and an antagonist of the 5-HT3, 5-HT1D, and 5-HT7 receptors. … Some serotonin receptors seem to play a relatively neutral or insignificant role in the regulation of mood, but others, such as 5-HT1A autoreceptors and 5-HT7 receptors, appear to play an oppositional

    Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-RingProducts: KELAC 5 MG, KELAC® 20 MG
  6. Drug

    Miglitol

    go.drugbank.com/drugs/DB00491
    Approved

    Miglitol should be taken at the start of a meal for maximal effect and the effect will depend on the amount of poly and oligosaccharides in the diet. … It is primarily used in diabetes mellitus type 2 for establishing greater glycemic control by preventing the digestion of carbohydrates (such as disaccharides, oligosaccharides, and polysaccharides) into

    Categories: Heterocyclic Compounds, 1-Ring, Drugs Used in DiabetesProducts: DIASTABOL 50 MG, DIASTABOL 100 MG
  7. Drug

    Eltrombopag

    go.drugbank.com/drugs/DB06210
    ApprovedInvestigational

    ITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelets in the blood. … Eltrombopag has also been recently approved (late 2012) for the treatment of thrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C to allow them to initiate and maintain interferon-based

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesProducts: REVOLADE® TABLETAS 25 MG, REVOLADE ® TABLETAS 50 MG
  8. Drug

    Manganese gluconate

    go.drugbank.com/drugs/DB11141
    Approved

    Manganese gluconate is a direct ingredient in food substances as a nutrient supplement. In pharmaceutical preparations it is used as a [DB06757] supplement. … Manganese gluconate is a manganese salt of gluconic acid with the chemical formula C12H22MnO14 x 2H2O.

    Mixtures: Cal-mag Plus K, Mn and Zn Caplets, E 400iu W Selenium 100mcgSynonyms: Manganese D-gluconate
  9. Drug

    Canagliflozin

    go.drugbank.com/drugs/DB08907
    ApprovedInvestigational

    Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise … It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 for a second indication of reducing the risk of cardiovascular events in patients diagnosed with type

    Mixtures: VOKANAMET ® TM_TABLETAS RECUBIERTAS 150/1000 MG, VOKANAMET 50 MG/500 MGCategories: Drugs Used in Diabetes, Cytochrome P-450 Substrates
  10. Drug

    Hydroxyurea

    go.drugbank.com/drugs/DB01005
    ApprovedInvestigational

    Hydroxyurea is a non-alkylating antineoplastic agent that was first synthesized in 1869 but was not characterized biologically until 1928. … [A262596] It was first approved by the FDA in 1998 for the treatment of sickle cell anemia in adults.

    Categories: Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 Enzyme InhibitorsSynonyms: N-Hydroxyurea, N-Carbamoylhydroxylamine